0 356

Cited 241 times in

Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes

DC FieldValueLanguage
dc.contributor.author최성희-
dc.contributor.author고영국-
dc.contributor.author김수경-
dc.contributor.author안철우-
dc.contributor.author이현철-
dc.contributor.author임승길-
dc.contributor.author장양수-
dc.contributor.author차봉수-
dc.contributor.author최동훈-
dc.date.accessioned2015-07-14T16:34:25Z-
dc.date.available2015-07-14T16:34:25Z-
dc.date.issued2004-
dc.identifier.issn0149-5992-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/111165-
dc.description.abstractOBJECTIVE: Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging clinical problem. This study evaluated the efficacy of rosiglitazone for preventing in-stent restenosis in type 2 diabetic patients. RESEARCH DESIGN AND METHODS: We conducted a prospective, randomized, case-controlled trial involving 95 diabetic patients with CAD who were randomly assigned to either the control or rosiglitazone group (48 and 47 patients, respectively). Quantitative coronary angiography (QCA) was performed at study entry and again at 6-month follow-up. The primary end point was the restenosis rate, which was determined by QCA. RESULTS: Eighty-three patients (45 patients with 55 lesions in the control group and 38 patients with 51 lesions in the rosiglitazone group) completed follow-up angiography. Rosiglitazone treatment for 6 months reduced fasting insulin concentration. The high-sensitivity C-reactive protein concentration was significantly reduced in the rosiglitazone group compared with that in the control group (from 2.92 +/- 1.98 to 0.62 +/- 0.44 mg/l, P < 0.001 vs. from 2.01 +/- 1.33 to 1.79 +/- 1.22 mg/l, P = NS). However, the baseline and follow-up glucose and lipid concentrations were not different between two groups. The rate of in-stent restenosis was significantly reduced in the rosiglitazone group compared with the control group (for stent lesions: 17.6 vs. 38.2%, P = 0.030). The rosiglitazone group had a significantly lower degree of diameter stenosis (23.0 +/- 23.4% vs. 40.9 +/- 31.9%, P = 0.004) compared with the control group. CONCLUSIONS: We demonstrated that treatment with rosiglitazone significantly reduces in-stent restenosis in diabetic patients with CAD who underwent coronary stent implantation.-
dc.description.statementOfResponsibilityopen-
dc.format.extent2654~2660-
dc.relation.isPartOfDIABETES CARE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHCoronary Angiography-
dc.subject.MESHCoronary Restenosis/diagnostic imaging-
dc.subject.MESHCoronary Restenosis/prevention & control*-
dc.subject.MESHCoronary Stenosis/drug therapy-
dc.subject.MESHCoronary Stenosis/therapy*-
dc.subject.MESHDiabetes Mellitus, Type 2*/complications-
dc.subject.MESHDiabetic Angiopathies/drug therapy-
dc.subject.MESHDiabetic Angiopathies/etiology-
dc.subject.MESHDiabetic Angiopathies/therapy-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHHypoglycemic Agents/therapeutic use*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRosiglitazone-
dc.subject.MESHStents*-
dc.subject.MESHThiazolidinediones/therapeutic use*-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHVasodilator Agents/therapeutic use*-
dc.titlePreventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorChul-Woo Ahn-
dc.contributor.googleauthorDonghoon Choi-
dc.contributor.googleauthorBong-Soo Cha-
dc.contributor.googleauthorHyun-Chul Lee-
dc.contributor.googleauthorSung-Kil Lim-
dc.contributor.googleauthorYangsoo Jang-
dc.contributor.googleauthorYoung-Guk Ko-
dc.contributor.googleauthorSung-Hee Choi-
dc.contributor.googleauthorSoo-Kyung Kim-
dc.identifier.doi10.2337/diacare.27.11.2654-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA04087-
dc.contributor.localIdA00127-
dc.contributor.localIdA00630-
dc.contributor.localIdA02270-
dc.contributor.localIdA03301-
dc.contributor.localIdA03375-
dc.contributor.localIdA03448-
dc.contributor.localIdA03996-
dc.contributor.localIdA04053-
dc.relation.journalcodeJ00721-
dc.identifier.eissn1935-5548-
dc.identifier.pmid15505001-
dc.identifier.urlhttp://care.diabetesjournals.org/content/27/11/2654.long-
dc.subject.keywordCAD, coronary artery disease-
dc.subject.keywordhsCRP, high-sensitivity C-reactive protein-
dc.subject.keywordMLD, minimal lumen diameter-
dc.subject.keywordPPAR, peroxisome proliferator–activated receptor-
dc.subject.keywordQCA, quantitative coronary angiography-
dc.subject.keywordTZD, thiazolidinedione-
dc.subject.keywordVSMC, vascular smooth muscle cell-
dc.contributor.alternativeNameChoi, Seong Hee-
dc.contributor.alternativeNameKo, Young Guk-
dc.contributor.alternativeNameKim, Soo Kyung-
dc.contributor.alternativeNameAhn, Chul Woo-
dc.contributor.alternativeNameLee, Hyun Chul-
dc.contributor.alternativeNameLim, Sung Kil-
dc.contributor.alternativeNameJang, Yang Soo-
dc.contributor.alternativeNameCha, Bong Soo-
dc.contributor.alternativeNameChoi, Dong Hoon-
dc.contributor.affiliatedAuthorChoi, Seong Hee-
dc.contributor.affiliatedAuthorKo, Young Guk-
dc.contributor.affiliatedAuthorKim, Soo Kyung-
dc.contributor.affiliatedAuthorAhn, Chul Woo-
dc.contributor.affiliatedAuthorLee, Hyun Chul-
dc.contributor.affiliatedAuthorLim, Sung Kil-
dc.contributor.affiliatedAuthorJang, Yang Soo-
dc.contributor.affiliatedAuthorCha, Bong Soo-
dc.contributor.affiliatedAuthorChoi, Dong Hoon-
dc.rights.accessRightsnot free-
dc.citation.volume27-
dc.citation.number11-
dc.citation.startPage2654-
dc.citation.endPage2660-
dc.identifier.bibliographicCitationDIABETES CARE, Vol.27(11) : 2654-2660, 2004-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.